Domainex has expanded its assay services to include assay development and fragment-based screening using both biochemical and biophysical techniques. It has also launched a new collection of chemical fragments that is more diverse than other commercially available collections. This expansion allows Domainex to screen small molecules against various targets and identify hits using its in silico LeadBuilder technology.

1. Domainex announces the expansion of
its assay services and the launch of its
unique fragment-based screening
collection.
Cambridge, UK, 6th January 2012.
Domainex Ltd., the UK-based fully integrated drug discovery company
focused on speed and innovation, has significantly increased its discovery
service capabilities, to include assay development and fragment-based
screening.
This expansion enables Domainex to screen small molecule compounds
against a variety of enzymatic and protein-protein interaction targets, using
both biochemical and biophysical assay techniques. Domainex is able to
utilise its in silico LeadBuilder technology to identify hits and has invested
in the establishment of a new and unique collection of chemical fragments
to provide its clients with a diverse range of starting points for discovery
programs.
The fragment collection has considerable advantages over other
commercially-available collections of fragments, as it contains a more
diverse range of pharmacophores without any increase in lipophilicity. The
consequence of this is that Domainex’s fragment collection is likely to
reveal more potent hits than alternative collections and hits that can be
developable in the absence of an x-ray crystal structure.
Domainex offers fully integrated services in drug discovery which include
molecular biology, including its patented Combinatorial Domain Hunting
technology; protein purification and characterisation; assay development;
hit identification; computational chemistry and medicinal chemistry.
Domainex’s track record of delivery is superb, already resulting in five
candidate drugs for clients, three of which have entered clinical trials.
Dr Joanne McCudden, Head of Business Development at Domainex said:
“The addition of increased capacity and expansion of Domainex’s

2. capabilities in assay development and small molecule screening, offers our
clients a new and efficient way of finding hits against their drug targets.
Domainex’s fragment-based screening is particularly powerful when
coupled with Domainex’s unique protein expression capability, which
enables the rapid cloning of target proteins including those which can
otherwise be difficult. Domainex can now take a target through to a hit
within a few months in a very cost-effective way. Exactly what drug
discovery companies of all sizes need in the present demanding
environment”.
• For more information see: www.domainex.co.uk or contact:
Joanne McCudden
Head of Business Development
Joanne.mccudden@domainex.co.uk
Tel +44 (0)1993 201 801
Discovery Platform | Research Pipeline | Discovery Services | About Us
162 Cambridge Science Park, Cambridge, CB4 0GH
www.domainex.co.uk